In a patient with chronic kidney disease stage 3a (estimated glomerular filtration rate 58 mL/min/1.73 m²) on oral iron therapy with ferritin 26 ng/mL who is not improving, should I continue monitoring or initiate intravenous iron in collaboration with hematology?

Switch to Intravenous Iron Now

In a CKD stage 3a patient with ferritin 26 ng/mL who is not responding to oral iron, you should transition to intravenous iron therapy. This ferritin level indicates absolute iron deficiency, and oral iron failure in CKD patients warrants IV iron administration.

Why IV Iron is Indicated

Your patient has clear iron deficiency (ferritin 26 ng/mL is well below the 100 ng/mL threshold used to define iron deficiency in CKD) and has demonstrated oral iron failure 1. The KDIGO conferences on anemia management acknowledge that oral iron has poor gastrointestinal tolerance and adherence issues, particularly in CKD patients 2, 3.

Key diagnostic thresholds to confirm your decision:

• Ferritin <100 ng/mL defines iron deficiency in most CKD conditions 1
• Your patient's ferritin of 26 ng/mL is severely low
• Lack of improvement on oral iron indicates either malabsorption, non-adherence, or inadequate dosing—all of which are bypassed with IV administration

Evidence Supporting IV Iron in CKD Stage 3

Recent systematic review data show that IV iron significantly improves iron indices in non-dialysis CKD patients, with transferrin saturation increasing by +7.48% and ferritin by +208.83 ng/mL compared to oral iron or placebo 4. Importantly, no consistent safety signals were identified with IV iron use in this population 4.

A large Veterans Affairs cohort study found no increased risk of ESKD progression or mortality with IV versus oral iron in advanced CKD patients (eGFR <60), suggesting IV iron is safe when clinically indicated 5.

Treatment Targets

Aim for:

• Ferritin: 100-500 ng/mL (most guidelines recommend not exceeding 500 ng/mL in CKD) 1
• Transferrin saturation (TSAT): >20% 1, 6

Check TSAT if not already done—this helps confirm functional iron deficiency and guides therapy intensity.

Regarding Hematology Referral

You do not need hematology involvement for straightforward iron deficiency in CKD. This is within nephrology/primary care scope. Reserve hematology consultation for:

• Unexplained anemia despite iron repletion
• Concern for alternative diagnoses (hemolysis, bone marrow disorders)
• Need for erythropoiesis-stimulating agents (ESAs)

Practical Implementation

1. Order IV iron infusion (iron sucrose, ferric gluconate, or ferumoxytol—choice depends on your institution's formulary)
2. Recheck ferritin and TSAT in 4-6 weeks after initial IV iron course
3. Monitor hemoglobin to assess erythropoietic response
4. Consider repeat IV iron dosing if targets not met, rather than returning to oral iron

Important Caveat

One recent observational study suggested potential harm with iron supplementation in non-anemic CKD stage 3 women with low ferritin 7. However, this study had significant limitations (retrospective, residual confounding, no data on TSAT or iron dosing), and your patient appears to have failed oral therapy, suggesting true iron deficiency requiring correction. The weight of evidence supports iron repletion when deficiency is documented 4.

The KDIGO conferences explicitly call for more trials comparing oral versus IV iron in non-dialysis CKD at different eGFR levels 3, acknowledging current evidence gaps. However, in clinical practice with documented iron deficiency and oral iron failure, IV iron is the appropriate next step rather than continued monitoring of a worsening deficiency state.